| scholarly article | Q13442814 |
| P356 | DOI | 10.1024/0301-1526/A000723 |
| P698 | PubMed publication ID | 30205764 |
| P2093 | author name string | Birgit Linnemann | |
| P2860 | cites work | Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines | Q22255576 |
| VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632982 | ||
| A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) | Q28174751 | ||
| Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients | Q28195403 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| International consensus report on the investigation and management of primary immune thrombocytopenia | Q28262094 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Antiphospholipid Syndrome: Role of Vascular Endothelial Cells and Implications for Risk Stratification and Targeted Therapeutics | Q30234565 | ||
| The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study | Q30885847 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| The hematologic manifestations of the antiphospholipid syndrome | Q33379294 | ||
| Use of rituximab in the antiphospholipid syndrome | Q33389337 | ||
| Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q33399576 | ||
| A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome | Q33404206 | ||
| Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes | Q33408360 | ||
| Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. | Q33419171 | ||
| The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features | Q33420116 | ||
| How I treat catastrophic thrombotic syndromes. | Q33424463 | ||
| Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013). | Q33579089 | ||
| Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome | Q33723441 | ||
| Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug | Q33747286 | ||
| 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends | Q34400373 | ||
| Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) | Q36242479 | ||
| Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis | Q36302245 | ||
| Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers | Q36843689 | ||
| A randomized trial of rosuvastatin in the prevention of venous thromboembolism | Q37262627 | ||
| Revisiting Libman-Sacks endocarditis: a historical review and update | Q37352871 | ||
| Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 | ||
| Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression | Q37645693 | ||
| Neurological manifestations of antiphospholipid syndrome | Q37700770 | ||
| A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients | Q37702168 | ||
| What nephrologists need to know about antiphospholipid syndrome | Q37768573 | ||
| Dermatological manifestations of Hughes’ antiphospholipid antibody syndrome | Q37778646 | ||
| Strategies for managing heparin therapy in patients with antiphospholipid antibody syndrome | Q37961828 | ||
| Drug-induced lupus anticoagulants and antiphospholipid antibodies | Q37967416 | ||
| Guidelines on the investigation and management of antiphospholipid syndrome | Q37982121 | ||
| Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab | Q38115382 | ||
| Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature | Q38122121 | ||
| Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. | Q38159868 | ||
| Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis | Q38177962 | ||
| The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review | Q38221324 | ||
| Markers of cardiovascular risk in patients with antiphospholipid syndrome: a meta-analysis of literature studies | Q38259336 | ||
| Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. | Q38280730 | ||
| Neuropsychiatric presentations of antiphospholipid antibodies. | Q38436403 | ||
| Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome. | Q38753510 | ||
| Treatment of pregnancy-associated venous thromboembolism - position paper from the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH). | Q38802052 | ||
| Independent validation of the adjusted GAPSS. Role of thrombotic risk assessment in the real-life setting. | Q38848271 | ||
| IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis | Q38856073 | ||
| The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome. | Q38866404 | ||
| Detection of lupus anticoagulant in the era of direct oral anticoagulants | Q39042314 | ||
| Pathogenesis and management of antiphospholipid syndrome | Q39198671 | ||
| Clinical course of high-risk patients diagnosed with antiphospholipid syndrome | Q39934417 | ||
| The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. | Q40474976 | ||
| Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. | Q41595596 | ||
| Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome | Q43246259 | ||
| Statins for the treatment of antiphospholipid syndrome? | Q43275855 | ||
| Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. | Q43841492 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| What do we know about the cardiac valve lesion in the antiphospholipid syndrome (APS)? | Q44811981 | ||
| GAPSS: the Global Anti-Phospholipid Syndrome Score | Q44993606 | ||
| The global anti-phospholipid syndrome score in primary APS. | Q45130401 | ||
| Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: communication from the SSC of the ISTH. | Q45861938 | ||
| Screening for lupus anticoagulants in patients treated with vitamin K antagonists | Q45878162 | ||
| Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. | Q46651769 | ||
| Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome | Q49042052 | ||
| Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. | Q49085305 | ||
| Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome | Q49114215 | ||
| Genetic risk factors in thrombotic primary antiphospholipid syndrome: A systematic review with bioinformatic analyses. | Q49885292 | ||
| Thrombocytopenia in high-risk patients with antiphospholipid syndrome | Q50112309 | ||
| Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. | Q50619255 | ||
| Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. | Q51158264 | ||
| 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. | Q51289629 | ||
| Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. | Q51314663 | ||
| Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. | Q51342200 | ||
| Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients | Q53165981 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| Inhibition of the mTORC pathway in the antiphospholipid syndrome. | Q55072769 | ||
| Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal Transplantation | Q58048140 | ||
| A Comparison of Lupus Anticoagulant–Positive Patients With Clinical Picture of Antiphospholipid Syndrome and Those Without | Q61928680 | ||
| Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone | Q73143663 | ||
| Lupus anticoagulants and the risk of a first episode of deep venous thrombosis | Q81064718 | ||
| Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies | Q83389363 | ||
| First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss | Q83992557 | ||
| Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review | Q86613937 | ||
| Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk | Q86646346 | ||
| Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles | Q87279480 | ||
| Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study | Q87375739 | ||
| Renal involvement in antiphospholipid syndrome | Q87467570 | ||
| A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab | Q87495399 | ||
| Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome | Q87716666 | ||
| P433 | issue | 6 | |
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| P304 | page(s) | 451-464 | |
| P577 | publication date | 2018-09-12 | |
| P1433 | published in | Vasa | Q15767573 |
| P1476 | title | Antiphospholipid syndrome - an update | |
| P478 | volume | 47 |
| Q92983632 | Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance |
| Q99711409 | Lupus Antibody Mimicking Reduced Plasmatic Coagulation in a Patient With Atrial Fibrillation and Ischemic Stroke |
| Q90521167 | MicroRNA (miRNA): A New Dimension in the Pathogenesis of Antiphospholipid Syndrome (APS) |
| Q91868696 | Neutrophils-Important Communicators in Systemic Lupus Erythematosus and Antiphospholipid Syndrome |
| Q90766007 | Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies |
Search more.